2- Reduction in glucagon secretion GLP-1 suppresses inappropriate glucagon secretion from alpha cells then decrease post prandial glucose spikes Attended lively conversation on prudent off label use in T1D by expert provider at last June ADA Scientific sessions
More serious concerns include the risk of pancreatitis, gallbladder disease, andfor semaglutidepotential worsening of diabetic retinopathy in some patients
KWONG: This sounds like a tricky design problem
Semaglutide is a molecule belonging to the category of GLP-1 (glucagon-like peptide-1) receptor agonists that has been used for several years to treat type 2 diabetes
Furthermore, there was an increased risk of serious adverse events including an increased incidence of disturbances in diabetes control and diabetes diagnoses, as well as serious gastrointestinal, musculoskeletal, dermatological, infectious, and bleeding adverse events